Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases

Expert Opin Biol Ther. 2006 Sep;6(9):943-9. doi: 10.1517/14712598.6.9.943.

Abstract

B cells play an important role in the pathogenesis of many autoimmune diseases. Different approaches targeting the B cell compartment are under investigation. Selective modulation of B cells has been recently achieved using a humanised monoclonal antibody against the B cell surface marker CD22. This antibody (epratuzumab) was originally developed for the treatment of non-Hodgkin's lymphoma and was found to be effective, with a very good safety profile. Recent studies have demonstrated the efficacy and safety of epratuzumab in several autoimmune diseases, including systemic lupus erythematosus and primary Sjögren's syndrome.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Drug Administration Schedule
  • Drug Interactions
  • Drug Therapy, Combination
  • Humans
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / immunology
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / immunology
  • Randomized Controlled Trials as Topic
  • Sialic Acid Binding Ig-like Lectin 2 / immunology*
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Sialic Acid Binding Ig-like Lectin 2
  • epratuzumab